(JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib cream for topical use in dermatological indications worldwide ...

LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development. The pharmaceutical company’s Boston-based R&D ...

according to the second phase of the survey sponsored by LEO Pharma Inc., a global leader in medical dermatology, and conducted by Ipsos. The survey, which includes responses from 100 doctors and ...

To learn more about CHE, visit www.TalkCHE.com. LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with ...

More than 90% of dermatology clinicians surveyed by Leo Pharma say their patients with ... from eczema—though Leo’s delgocitinib cream, a topical JAK inhibitor dubbed Anzupgo, is currently ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

according to the second phase of the survey sponsored by LEO Pharma Inc., a global leader in medical dermatology, and conducted by Ipsos.

LEO Pharma and the Parker Institute at Copenhagen University Hospital have entered into a three-year academic partnership aimed at advancing dermatology research. The alliance will focus on enhancing ...